Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Beclin-1 implicated in diabetic cardiomyopathy

May 28, 2021

SPECTRA and PULSAR studies on sotatercept for treating PAH show promise

May 21, 2021

IMB-1018972 is safe and well tolerated in phase I study

May 20, 2021

Keros Therapeutics KER-012 shows promise for the treatment of PAH

May 20, 2021

Eccogene (Shanghai) identifies SSAO inhibitors

May 19, 2021

Promising effect of oral TRPC6 inhibitor BI-749327 on pulmonary hypertension

May 18, 2021

Sunshine Lake Pharma describes new mineralocorticoid receptor antagonists

May 14, 2021

Cereno and University of Michigan collaborate on preclinical development of CS-585

April 30, 2021

Enrollment opens in phase II/III study of MK-5475 in PAH

April 30, 2021

Vicore Pharma discloses AGTR2 agonists

April 9, 2021

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...